SMMT Q3 2024 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$19,999

Operating Income

-$58M

Net Income

-$56M

EPS (Diluted)

$-0.08

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$503M

Total Liabilities

$65M

Stockholders' Equity

$438M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$19,999	-$599,000	+96.7%
Operating Income	-$58M	-$20M	-183.6%
Net Income	-$56M	-$21M	-164.5%